Regeneron Pharmaceuticals's ROE % for the quarter that ended in Mar. 2026 was 9.34%. Regeneron Pharmaceuticals's PB Ratio for the quarter that ended in Mar. 2026 was 2.58.
Regeneron Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 3.62%.
Regeneron Pharmaceuticals ROE % Adjusted to Book Value Related Terms
Regeneron Pharmaceuticals ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Regeneron Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regeneron Pharmaceuticals ROE % Adjusted to Book Value Chart
STU:RGO vs ALNY, RVMD, ONC: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, Regeneron Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regeneron Pharmaceuticals ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Regeneron Pharmaceuticals's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 3.62% mean?
Regeneron Pharmaceuticals (STU:RGO) has a ROE % Adjusted to Book Value of 3.62% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Regeneron Pharmaceuticals and its competitors.
Is Regeneron Pharmaceuticals' ROE % Adjusted to Book Value too high?
Regeneron Pharmaceuticals' current ROE % Adjusted to Book Value is 3.62%. Overall, Regeneron Pharmaceuticals has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' ROE % Adjusted to Book Value compare to ALNY and RVMD?
Regeneron Pharmaceuticals' ROE % Adjusted to Book Value of 3.62% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Regeneron Pharmaceuticals and its competitors. Regeneron Pharmaceuticals's current ROE % Adjusted to Book Value is 3.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (STU:RGO) is currently considered Modestly Undervalued. The stock's GF Value™ is €783.00, compared to a current price of €568.10 — trading 27.4% below its estimated fair value. The current ROE % Adjusted to Book Value is 3.62%. Regeneron Pharmaceuticals' overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Regeneron Pharmaceuticals (STU:RGO), the current ROE % Adjusted to Book Value is 3.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Regeneron Pharmaceuticals (STU:RGO) Overvalued in 2026?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued.
The current stock price of €568.10 is trading 27.4% below its estimated GF Value™ of €783.00.
GuruFocus considers Regeneron Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for STU:RGO:
ROE % Adjusted to Book Value: 3.62%
GF Value™: €783.00 vs. price of €568.10 (27.4% below fair value)
No single metric tells the full story. See the STU:RGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
83GF Score
Get the complete analysis for STU:RGO
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:RGO has been successfully added to your 
